Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGMO's Cash to Debt is ranked higher than
98% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. SGMO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SGMO' s 10-Year Cash to Debt Range
Min: 1.71   Max: No Debt
Current: No Debt

Equity to Asset 0.87
SGMO's Equity to Asset is ranked higher than
77% of the 599 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SGMO: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
SGMO' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.99
Current: 0.87

0.39
0.99
Interest Coverage No Debt
SGMO's Interest Coverage is ranked higher than
97% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGMO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 15.20
M-Score: -2.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -49.55
SGMO's Operating margin (%) is ranked higher than
55% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. SGMO: -49.55 )
Ranked among companies with meaningful Operating margin (%) only.
SGMO' s 10-Year Operating margin (%) Range
Min: -1114.07   Max: -50.32
Current: -49.55

-1114.07
-50.32
Net-margin (%) -47.15
SGMO's Net-margin (%) is ranked higher than
54% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. SGMO: -47.15 )
Ranked among companies with meaningful Net-margin (%) only.
SGMO' s 10-Year Net-margin (%) Range
Min: -1050.8   Max: -48.73
Current: -47.15

-1050.8
-48.73
ROE (%) -11.44
SGMO's ROE (%) is ranked higher than
62% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. SGMO: -11.44 )
Ranked among companies with meaningful ROE (%) only.
SGMO' s 10-Year ROE (%) Range
Min: -67.23   Max: -16.09
Current: -11.44

-67.23
-16.09
ROA (%) -9.78
SGMO's ROA (%) is ranked higher than
62% of the 835 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. SGMO: -9.78 )
Ranked among companies with meaningful ROA (%) only.
SGMO' s 10-Year ROA (%) Range
Min: -60.12   Max: -13.76
Current: -9.78

-60.12
-13.76
ROC (Joel Greenblatt) (%) -1399.42
SGMO's ROC (Joel Greenblatt) (%) is ranked lower than
66% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -353.07 vs. SGMO: -1399.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3614.47   Max: -703.47
Current: -1399.42

-3614.47
-703.47
Revenue Growth (3Y)(%) 50.40
SGMO's Revenue Growth (3Y)(%) is ranked higher than
92% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. SGMO: 50.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGMO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -38   Max: 68.7
Current: 50.4

-38
68.7
EBITDA Growth (3Y)(%) -17.70
SGMO's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. SGMO: -17.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGMO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -23.7   Max: 106.7
Current: -17.7

-23.7
106.7
EPS Growth (3Y)(%) -18.10
SGMO's EPS Growth (3Y)(%) is ranked lower than
65% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SGMO: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGMO' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.2   Max: 184.4
Current: -18.1

-25.2
184.4
» SGMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SGMO Guru Trades in Q2 2014

First Eagle Investment 536,380 sh (+34.10%)
Steven Cohen 788,900 sh (unchged)
First Eagle Investment 2,500 sh (unchged)
» More
Q3 2014

SGMO Guru Trades in Q3 2014

First Eagle Investment 4,000 sh (unchged)
Steven Cohen 488,400 sh (unchged)
First Eagle Investment 536,380 sh (unchged)
Steven Cohen 641,500 sh (-18.68%)
» More
Q4 2014

SGMO Guru Trades in Q4 2014

Joel Greenblatt 17,441 sh (New)
Paul Tudor Jones 17,511 sh (New)
First Eagle Investment 559,780 sh (+4.36%)
First Eagle Investment 4,017 sh (unchged)
Steven Cohen 158,000 sh (-75.37%)
» More
Q1 2015

SGMO Guru Trades in Q1 2015

Steven Cohen 196,100 sh (+24.11%)
First Eagle Investment 559,780 sh (unchged)
First Eagle Investment 4,017 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 0.34
SGMO's Forward P/E is ranked higher than
100% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 21.19 vs. SGMO: 0.34 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.10
SGMO's P/B is ranked higher than
55% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. SGMO: 4.10 )
Ranked among companies with meaningful P/B only.
SGMO' s 10-Year P/B Range
Min: 1.48   Max: 11.1
Current: 4.1

1.48
11.1
P/S 16.39
SGMO's P/S is ranked lower than
57% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.45 vs. SGMO: 16.39 )
Ranked among companies with meaningful P/S only.
SGMO' s 10-Year P/S Range
Min: 4.84   Max: 129.75
Current: 16.39

4.84
129.75
Current Ratio 10.21
SGMO's Current Ratio is ranked higher than
75% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. SGMO: 10.21 )
Ranked among companies with meaningful Current Ratio only.
SGMO' s 10-Year Current Ratio Range
Min: 5.06   Max: 55.31
Current: 10.21

5.06
55.31
Quick Ratio 10.21
SGMO's Quick Ratio is ranked higher than
76% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. SGMO: 10.21 )
Ranked among companies with meaningful Quick Ratio only.
SGMO' s 10-Year Quick Ratio Range
Min: 5.06   Max: 55.31
Current: 10.21

5.06
55.31
Days Sales Outstanding 47.28
SGMO's Days Sales Outstanding is ranked higher than
66% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. SGMO: 47.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGMO' s 10-Year Days Sales Outstanding Range
Min: 1.14   Max: 284.62
Current: 47.28

1.14
284.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.20
SGMO's Price/Net Cash is ranked higher than
72% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. SGMO: 5.20 )
Ranked among companies with meaningful Price/Net Cash only.
SGMO' s 10-Year Price/Net Cash Range
Min: 0.96   Max: 17.78
Current: 5.2

0.96
17.78
Price/Net Current Asset Value 5.00
SGMO's Price/Net Current Asset Value is ranked higher than
72% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. SGMO: 5.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGMO' s 10-Year Price/Net Current Asset Value Range
Min: 0.93   Max: 17.45
Current: 5

0.93
17.45
Price/Tangible Book 4.10
SGMO's Price/Tangible Book is ranked higher than
66% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. SGMO: 4.10 )
Ranked among companies with meaningful Price/Tangible Book only.
SGMO' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 12.58
Current: 4.1

0.89
12.58
Price/DCF (Projected) 76.60
SGMO's Price/DCF (Projected) is ranked lower than
93% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SGMO: 76.60 )
Ranked among companies with meaningful Price/DCF (Projected) only.
SGMO' s 10-Year Price/DCF (Projected) Range
Min: 21.15   Max: 98
Current: 76.6

21.15
98
Price/Median PS Value 0.70
SGMO's Price/Median PS Value is ranked higher than
84% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SGMO: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
SGMO' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 7.61
Current: 0.7

0.25
7.61
Earnings Yield (Greenblatt) -3.90
SGMO's Earnings Yield (Greenblatt) is ranked higher than
62% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.60 vs. SGMO: -3.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SGMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.2   Max: 0
Current: -3.9

-4.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBY.Germany,
Sangamo BioSciences Inc was incorporated in June 1995 in the state of Delaware. It is a clinical stage biopharmaceutical that company engaged in the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. The Company is engaged in the development of novel human therapeutics and is building a pipeline of ZFP Therapeutics. Its ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 2 and two Phase 1/2 clinical trials. It has preclinical ZFP Therapeutic development programs in hemophilia and Parkinsons disease. In addition, it has research stage programs in other monogenic diseases; genetic conditions that result from a defect in a single gene, including hemoglobinopathies such as sickle cell anemia, lysosomal storage diseases and certain immunodeficiencies. On 8 January 2014, the Company has a collaborative partnership with Biogen Idec Inc.to research, develop and commercialize our preclinical ZFP Therapeutic development program, in hemoglobinopathies, and targeting sickle cell disease (SCD) and beta-thalassemia. It has a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon its ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr and is selling transgenic animals through its SAGETM Labs business unit. The Company has a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, it has provided DAS with access to its ZFP technology and the exclusive rights to use it to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. DAS markets its ZFN technology under the trademark EXZACTTM Precision Technology. The Company has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic, or prophylactic purposes. It faces competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies; for establishing relationships with academic and research institutions; and for licenses to proprietary technology. Its therapeutic or pharmaceutical products undergoes rigorous preclinical testing and clinical trials in humans and an extensive regulatory clearance process implemented by the U.S. Food and Drug Administration (FDA) under the federal Food, Drug and Cosmetic Act.
» More Articles for SGMO

Headlines

Articles On GuruFocus.com
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 03 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2009 
Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results Feb 04 2009 

More From Other Websites
MKM Partners' 4 Health Care Stocks to Sell Before June May 27 2015
Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference May 26 2015
Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference May 26 2015
Sangamo BioSciences Presents New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storge... May 18 2015
Sangamo BioSciences Presents New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storge... May 18 2015
Sangamo BioSciences Provides Clinical Update On SB-728-T Program and Developments In Other ZFP... May 14 2015
Sangamo BioSciences Provides Clinical Update On SB-728-T Program and Developments In Other ZFP... May 14 2015
Sangamo BioSciences Announces Joint Steering Committee Decision To Consolidate ZFP Therapeutic®... May 13 2015
Sangamo BioSciences Announces Joint Steering Committee Decision To Consolidate ZFP Therapeutic®... May 13 2015
Sangamo BioSciences Announces Presentation At The UBS 2015 Global Healthcare Conference May 12 2015
Sangamo BioSciences Announces Presentation At The UBS 2015 Global Healthcare Conference May 12 2015
Sangamo BioSciences Announces Presentation At The Bank Of America Merrill Lynch 2015 Health Care... May 07 2015
10-Q for Sangamo BioSciences, Inc. Apr 30 2015
Sangamo BioSciences And Collaborators To Present Data On ZFP Therapeutic Applications At Annual... Apr 29 2015
Gene Therapy Stocks Take Beating On Bad News For Celladon Apr 27 2015
First experiment 'editing' human embryos ignites ethical furor Apr 23 2015
First experiment 'editing' human embryos ignites ethical furor Apr 23 2015
First experiment 'editing' human embryos ignites ethical furor Apr 23 2015
Street Talk: SKX, FFIV, STJ, TCBI & SGMO Apr 23 2015
Sangamo BioSciences Inc Earnings Call scheduled for 5:00 pm ET today Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK